CSBio CSBio

X
[{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$757.2 million","upfrontCash":"$310.4 million","newsHeadline":"Divestment of Aspen\u2019s European Thrombosis Business to Mylan and Withdrawal of Cautionary","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Aspen Pharmacare Holdings"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.

            Lead Product(s): Fondaparinux Sodium

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arixtra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Viatris

            Deal Size: $757.2 million Upfront Cash: $310.4 million

            Deal Type: Acquisition September 08, 2020

            Aspen API Comapny Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier
            Post Enquiry
            POST ENQUIRY